Dr. Rudick is an independent consultant having spent decades as an industry and academic leader, and in clinical practice. Most recently he was Vice President, Development Science, and Director of the Value Based Medicine MS Innovation Hub at Biogen. Dr. Rudick’s research has focused on experimental therapeutics, including innovative approaches to measuring immunologic, clinical, and imaging features of the disease for use in clinical research and practice. He played key roles in development of IFNß-1a (Avonex) and natalizumab (Tysabri) for relapsing forms of MS. For 30 years, his clinical practice focused on diagnosis and management of MS patients. He directed the Mellen Center at the Cleveland Clinic where he also had roles as the Chief Clinical Research Officer and Vice Chairman for Research and Development in the Neurological Institute.